1,404
Views
0
CrossRef citations to date
0
Altmetric
Coronavirus – Research Article

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital

, , , , , , , , , , & show all
Article: 2104058 | Received 01 Jun 2022, Accepted 18 Jul 2022, Published online: 17 Aug 2022

References

  • WHO Coronavirus (COVID-19) Dashboard: 263,563,622 confirmed cases and 5,232,562 deaths from COVID-19 pandemic [Internet]. [accessed 2022 Apr 8]. https://covid19.who.int/.
  • Pathania AS, Prathipati P, Abdul BA, Chava S, Katta SS, Gupta SC, Gangula PR, Pandey MK, Durden DL, Byrareddy SN et al. COVID-19 and cancer comorbidity: therapeutic opportunities and challenges. Theranostics. 2021;11(2):1–8. PMID: 33391502; PMCID: PMC7738845. doi:10.7150/thno.51471.
  • Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med. 2021;18(1):298–307. PMID: 33628602; PMCID: PMC7877167. doi:10.20892/j.issn.2095-3941.2020.0559.
  • He Y, Ding Y, Cao B, Huang Y, Wang X. COVID-19 vaccine development from the perspective of cancer patients. Hum Vaccin Immunother. 2021;17(10):3281–3287. Epub 2021 Jun 25. PMID: 34170788; PMCID: PMC8437497. doi:10.1080/21645515.2021.1943988.
  • Rajan S, Akhtar N, Sharma S, Chakrabarti D, Kumar V. COVID-19 vaccination for cancer patients: evidence, priority, and practice. Vaccine. 2021;39(36):5075–5077. Epub 2021 Jul 24. PMID: 34340859; PMCID: PMC8302852. doi:10.1016/j.vaccine.2021.07.063.
  • Nordøy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, Kolstad A. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol. 2002;19:71–78. PMID: 12180483. doi:10.1385/MO:19:2:71.
  • Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–778. Epub 2021 Apr 27. PMID: 33930323; PMCID: PMC8078907. doi:10.1016/S1470-2045(21)00213-8.
  • Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, Benouaich-Amiel A, Ben-Zvi H, Moskovits N, Brenner B, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133–1140. PMID: 34047765; PMCID: PMC8164144. doi:10.1001/jamaoncol.2021.2155.
  • Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74. Epub 2020 Dec 8. PMID: 33306990; PMCID: PMC7832220. doi:10.1016/S0140-6736(20)32623-4.
  • Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis. Eur J Cancer. 2021;159:259–274. Epub 2021 Oct 25. PMID: 34798454; PMCID: PMC8542448. doi:10.1016/j.ejca.2021.10.013.
  • Heudel P, Favier B, Assaad S, Zrounba P, Blay J-Y. Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients. Ann Oncol. 2021:1e2. Epub 2021 Jul 30. PMID: 34333128; PMCID: PMC8321960. doi:10.1016/j.annonc.2021.07.012.
  • Riester E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, Pessl F, Laengin T, Niederhauser C. Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. J Virol Methods. 2021;297:114271. Epub 2021 Jul 30. PMID: 34333128; PMCID: PMC8321960. doi:10.1016/j.annonc.2021.07.012.
  • Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S, Knezevic I. WHO international standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347–1348. Epub 2021 Mar 23. PMID: 33770519; PMCID: PMC7987302. doi:10.1016/S0140-6736(21)00527-4.
  • Resman Rus K, Korva M, Knap N, Avšič Županc T, Poljak M. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. J Clin Virol. 2021;139:104820. Epub 2021 Apr 10. PMID: 33865031; PMCID: PMC8035809. doi:10.1016/j.jcv.2021.104820.
  • Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, et al. AstraZeneca AZD1222 clinical study group. Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCov-19) COVID-19 vaccine. N Engl J Med. 2021;385(25):2348–2360. Epub 2021 Sep 29. PMID: 34587382; PMCID: PMC8522798. doi:10.1056/NEJMoa2105290.
  • Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-Dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdox1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891. Epub 2021 Feb 19. Erratum in: Lancet. 2021 Mar 6;397(10277):880. PMID: 33617777; PMCID: PMC7894131. doi:10.1016/S0140-6736(21)00432-3.
  • Cavanna L, Citterio C, Biasini C, Madaro S, Bacchetta N, Lis A, Cremona G, Muroni M, Bernuzzi P, Lo Cascio G, et al. COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy. Eur J Cancer. 2021;157:441–449. Epub 2021 Sep 2. PMID: 34601285; PMCID: PMC8410513. doi:10.1016/j.ejca.2021.08.035.
  • Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, Kaklamani V, Dietrich P-Y, Taylor BS, Simand P-F, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091–1098.e2. Epub 2021 Jun 18. PMID: 34214473; PMCID: PMC8218532. doi:10.1016/j.ccell.2021.06.009.
  • Linardou H, Spanakis N, Koliou GA, Christopoulou A, Karageorgopoulou S, Alevra N, Vagionas A, Tsoukalas N, Sgourou S, Fountzilas E, et al. Responses to SARS-CoV-2 vaccination in patients with cancer (ReCover Study): a prospective cohort study of the Hellenic Cooperative Oncology Group. Cancers (Basel). 2021;13(18):4621. PMID: 34572848; PMCID: PMC8466969. doi:10.3390/cancers13184621.
  • Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genomics. 2019;13(1):2. PMID: 30621780; PMCID: PMC6325731. doi:10.1186/s40246-018-0185-z.
  • Ahmed SB, Dumanski SM. Sex, gender and COVID-19: a call to action. Can J Public Health. 2020;111(6):980–983. Epub 2020 Sep 29. PMID: 32990927; PMCID: PMC7523484. doi:10.17269/s41997-020-00417-z.
  • Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol Oncol. 2021;14(1):38. PMID: 33640005; PMCID: PMC7910769. doi:10.1186/s13045-021-01046-w.
  • Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73. PMID: 18097448. doi:10.1038/nri2216.
  • Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016 Jan 26;18(1):10. PMID: 26810608; PMCID: PMC4727393. doi:10.1186/s13058-015-0669-x.
  • Jackson-Spence F, Toms C, Yang Y-H, Walshaw L, Riddell A, Cutino-Moguel M-T. The effect of anti-cancer therapy on immunologic response to COVID-19 vaccination. Presented at ASCO GU 2022. 2022 Feb 17–19. Abstract 319.
  • Chumsri S, Advani PP, Pai TS, Li Z, Mummareddy A, Acampora M, Reynolds GA, Wylie N, Boyle AW, Lou Y, et al. Humoral responses after SARS-CoV-2 mRNA vaccination and breakthrough infection in cancer patients. Mayo Clin Proc Innov Qual Outcomes. 2022;6(2):120–125. Epub 2021 Dec 13. PMID: 34926993; PMCID: PMC8666324. doi:10.1016/j.mayocpiqo.2021.12.004.
  • Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M, Geredeli Ç, Öztürk A, Perkin P, Demirtaş D, Erdemoglu E, et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol. 2022;18(10):1235–1244. Epub 2022 Jan 27. PMID: 35081732; PMCID: PMC8793921. doi:10.2217/fon-2021-1248.
  • Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. Epub 2021 May 17. PMID: 34002089. doi:10.1038/s41591-021-01377-8.